---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-26-000021"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2026-07-06T20:12:09+00:00"
generated_at: "2026-07-06T20:13:07.504332+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AbbVie lowers Q2 and FY 2026 adjusted EPS guidance by $0.17 on $291M IPR&D expense

## Summary
- Q2 2026 adjusted diluted EPS guidance reduced to $3.57-$3.61 from $3.74-$3.78.
- Full-year 2026 adjusted diluted EPS guidance reduced to $13.91-$14.11 from $14.08-$14.28.
- $291M pre-tax acquired IPR&D and milestones expense incurred in Q2 2026.
- Expense relates to collaborations, licensing, and asset acquisitions; not previously forecasted.

## SEC filing metadata
- accession: 0001551152-26-000021
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2026-07-06T20:12:09+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/0001551152-26-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000021/abbv-20260706.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-26-000021
- JSON: https://secwatch.observer/filing/0001551152-26-000021.json
- Plain text: https://secwatch.observer/filing/0001551152-26-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.